| Literature DB >> 26839876 |
Soo Yun Jang1, Seong-Woong Kang2, Won Ah Choi2, Jang Woo Lee2, Mi Ri Suh2, Song Mi Lee3, Yoo Kyoung Park1.
Abstract
In myopathy patients, fat mass increases as the disease progresses, while lean body mass decreases. The present study aimed to investigate the overall nutritional status of Korean myopathy patients through surveys of diet and dietary habits, bioelectrical impedance analysis (BIA), and biochemistry tests, as well as the examination of related factors, for the purpose of using such findings as a basis for improving the nutritional status in myopathy patients. The energy intake of all participants was found to be insufficient at only 44.5% of Dietary Reference Intakes for Koreans 2010 (KDRIs 2010), whereas protein intake was sufficient at 89.8% of KDRIs 2010. Dietary fiber intake was found to be 58.4% of sufficient dietary fiber intake for adults according to KDRIs 2010. Calcium intake was found to be 55.0% and magnesium was 14.9% of the recommended calcium and magnesium intake for adults according to KDRIs 2010. With respect to quality of life (QOL), overall increase in QOL domain score showed significant positive correlations with vegetable fat intake (p < 0.05), vegetable protein intake (p < 0.05), and dietary fiber intake (p < 0.05). With respect to BIA, the mean phage angle of all participants was found to be 2.49 ± 0.93°, which was below the cutoff value. As a study that examined nutrient analysis and dietary habits of myopathy patients in Korea, the present study is meaningful in providing the basic data for future studies that aim to present dietary guidelines for patients suffering from myopathy.Entities:
Keywords: Bioelectrical impedance analysis; Myopathy patients; Nutritional intake; Nutritional status; Phage angle
Year: 2016 PMID: 26839876 PMCID: PMC4731861 DOI: 10.7762/cnr.2016.5.1.43
Source DB: PubMed Journal: Clin Nutr Res ISSN: 2287-3732
General characteristics of subjects
| Variable | 10-19 y | 20-29 y | 30-39 y | > = 40 y | Total | p for trend |
|---|---|---|---|---|---|---|
| Age, years | 16.3 ± 2.7* | 23.8 ± 2.5 | 34.1 ± 3.2 | 50.1 ± 7.0 | 28.0 ± 11.7 | < 0.001‡ |
| Gender | ||||||
| Male | 14 | 35 | 10 | 6 | 65 | |
| Female | 1 | 2 | 1 | 6 | 10 | |
| Diagnosis | ||||||
| Duchenne muscular dystrophy | 8 | 25 | 3 | 1 | 37 | |
| Progressive muscular dystrophy | 5 | 10 | 6 | 3 | 24 | |
| Myotonic muscular dystrophy | 0 | 0 | 0 | 6 | 6 | |
| Limb-girdle muscular dystrophy | 0 | 1 | 0 | 2 | 3 | |
| Myotubular (centronuclear) myopathy | 1 | 1 | 0 | 0 | 2 | |
| Facioscapulohumeral muscular dystrophy | 0 | 0 | 1 | 0 | 1 | |
| Emery-Dreifuss muscular dystrophy | 0 | 0 | 1 | 0 | 1 | |
| Congenital myopathy | 1 | 0 | 0 | 0 | 1 | |
| Weight, kg | 38.6 ± 17.0 | 39.0 ± 14.4 | 46.5 ± 21.1 | 59.8 ± 18.8 | 43.3 ± 18.0 | 0.005‡ |
| Height, cm | 154.0 ± 14.5 | 157.8 ± 8.8 | 158.5 ± 12.1 | 160.6 ± 7.7 | 157.6 ± 10.5 | 0.223 |
| BMI, kg/m2 | 16.2 ± 6.4 | 15.7 ± 5.8 | 18.0 ± 6.7 | 23.2 ± 7.1 | 17.3 ± 6.6 | 0.014† |
| PIBW, % | 73.9 ± 28.9 | 71.4 ± 26.0 | 82.2 ± 30.4 | 108.2 ± 34.5 | 79.4 ± 30.7 | 0.014† |
BMI: body mass index, PIBW: percentage of ideal body weight.
*Mean ± SD; Significance as determined by Jonckheere-Terpstra test, p for trend less than †p < 0.05; ‡p < 0.01.
Pearson correlation coefficient of general characteristics, blood index and bioelectrical impedance analysis (BIA)
| Variable | Age, years | Height, cm | Weight, kg | Body mass index, kg/m2 | Phage angle,° |
|---|---|---|---|---|---|
| Age, years | 1.000 | ||||
| Height, cm | 0.446† | 1.000 | |||
| Weight, kg | 0.139 | 0.345† | 1.000 | ||
| Body mass index, kg/m2 | 0.428† | 0.954† | 0.068 | 1.000 | |
| Phage angle,° | -0.048 | -0.297* | -0.139 | -0.288* | 1.000 |
| Total Protein, g/dL | -0.131 | -0.050 | -0.117 | -0.009 | 0.235* |
| Cholesterol, mg/dL | 0.302† | 0.345† | -0.091 | 0.399† | 0.033 |
| Albumin, g/dL | -0.412† | -0.147 | -0.166 | -0.091 | 0.204 |
| Hemoglobin, g/dL | -0.283* | 0.125 | 0.054 | 0.126 | 0.152 |
| Hematocrit, % | -0.246* | 0.177 | 0.040 | 0.192 | 0.141 |
| Creatinine, mg/dL | 0.059† | 0.279* | 0.241* | 0.225 | -0.025 |
PhA: phase angle, between 3° and 15° in the majority of human beings.
Significance as determined by the Pearson correlation method, p for trend less than *p < 0.05; †p < 0.01.
Pearson correlation coefficient of nutrient analysis, blood index, and quality of life (QOL)
| Variable | Energy, kcal | Total fat, g | Vegetable fat, g | Total protein, g | Plant protein, g | Animal protein, g | Dietary fiber, g |
|---|---|---|---|---|---|---|---|
| Albumin, g/dL | 0.284* | 0.266* | 0.194 | 0.273* | 0.147 | 0.267* | 0.119 |
| Hemoglobin, g/dL | 0.265* | 0.248* | 0.208 | 0.289* | 0.139 | 0.295* | 0.107 |
| Overall Quality of Life and General Health | 0.173 | 0.106 | 0.261* | 0.209 | 0.267* | 0.086 | 0.305* |
Significance as determined by the Pearson correlation method, p for trend less than *p < 0.05; †p < 0.01.
General chemistry in subjects
| Variable | 10-19 y | 20-29 y | 30-39 y | > = 40 y | p for trend | Reference value |
|---|---|---|---|---|---|---|
| Calcium, mg/dL | 8.9 ± 0.3* | 8.9 ± 0.5 | 8.7 ± 0.4 | 8.8 ± 0.4 | 0.182 | 8.5-10.1 |
| Inorganic P, mg/dL | 4.4 ± 0.5 | 3.6 ± 0.8 | 3.5 ± 0.6 | 3.4 ± 0.6 | 0.001‡ | 2.9-4.6 |
| Glucose, mg/dL | 87.2 ± 7.4 | 88.9 ± 17.3 | 80.5 ± 10.6 | 103.7 ± 18.0 | 0.215 | 80-118 |
| BUN, mg/dL | 10.6 ± 2.0 | 11.8 ± 5.9 | 12.1 ± 4.0 | 9.6 ± 3.6 | 0.694 | 8.6-23.0 |
| Creatinine, mg/dL | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.3 ± 0.2 | 0.002‡ | 0.72-1.18 |
| Uric Acid, mg/dL | 5.8 ± 0.9 | 5.1 ± 1.1 | 5.3 ± 1.6 | 4.6 ± 1.1 | 0.040‡ | 3.5-8.0 |
| Cholesterol, mg/dL | 131.6 ± 29.1 | 137.8 ± 30.4 | 148.6 ± 29.4 | 165.3 ± 49.9 | 0.007‡ | 130-220 |
| Total Protein, g/dL | 6.6 ± 0.6 | 6.7 ± 0.5 | 6.8 ± 0.5 | 6.5 ± 0.6 | 0.758 | 6.9-8.3 |
| Albumin, g/dL | 4.2 ± 0.4 | 4.1 ± 0.3 | 4.1 ± 0.3 | 3.6 ± 0.3 | 0.001‡ | 3.4-5.3 |
| Total Bilirubin, mg/dL | 1.0 ± 0.4 | 1.0 ± 0.6 | 1.0 ± 0.6 | 0.7 ± 0.3 | 0.060 | 0.3-1.8 |
| ALP, IU/L | 113.7 ± 50.5 | 69.7 ± 23.6 | 68.9 ± 13.3 | 103.3 ± 64.0 | 0.509 | 44-99 |
| AST, IU/L | 35.7 ± 13.5 | 33.9 ± 14.2 | 30.1 ± 8.9 | 50.2 ± 27.9 | 0.422 | 16-37 |
| ALT, IU/L | 30.1 ± 22.3 | 29.3 ± 20.2 | 23.5 ± 7.6 | 42.3 ± 25.9 | 0.301 | 11-46 |
| LD, IU/L | 488.5 ± 130.4 | 401.4 ± 93.7 | 378.7 ± 53.1 | 462.8 ± 174.9 | 0.194 | 225-455 |
| CK, U/L | 953.4 ± 829.7 | 659.6 ± 870.0 | 257.8 ± 294.6 | 765.0 ± 1444.4 | 0.009‡ | 35-232 |
| CK-MB, mcg/L | 23.1 ± 19.2 | 13.6 ± 16.7 | 7.2 ± 7.9 | 13.4 ± 23.0 | 0.002‡ | 0-6.73 |
| Na, mmol/L | 137.4 ± 2.0 | 137.6 ± 2.0 | 137.8 ± 2.0 | 136.9 ± 4.8 | 0.959 | 138-146 |
| K, mmol/L | 3.9 ± 0.3 | 3.9 ± 0.3 | 3.9 ± 0.3 | 3.9 ± 0.5 | 0.641 | 3.6-4.8 |
| Cl, mmol/L | 104.3 ± 3.1 | 103.1 ± 3.1 | 103.5 ± 2.2 | 102.8 ± 5.4 | 0.516 | 96-107 |
| tCO2, mmol/L | 24.5 ± 3.4 | 26.4 ± 4.3 | 26.7 ± 3.6 | 28.5 ± 5.2 | 0.016 | 24-32 |
| eGFR (CKD-EPI), mL/min/1.73 m2 | 332.9 ± 41.9 | 328.1 ± 82.4 | 290.2 ± 57.5 | 171.3 ± 50.6 | 0.143 | |
| Albumin globulin ratio | 1.7 ± 0.3 | 1.6 ± 0.3 | 1.6 ± 0.2 | 1.3 ± 0.3 | 0.010† | 1.43-2.57 |
| BNP, pg/mL | 307.6 ± 687.2 | 30.6 ± 34.7 | 36.4 ± 39.5 | 50.5 ± 57.7 | 0.615 | 0-100 |
BUN: blood urea nitrogen, ALP: alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LD: lactate dehydrogenase, CK: creatine kinase, eGFR: estimated glomerular filtration rate, BNP: B type natriuretic peptide.
*Mean ± SD; Significance as determined by Jonckheere-Terpstra test, p for trend less than †p < 0.05; ‡p < 0.01.
Complete blood count in subjects
| Variable | 10-19 y | 20-29 y | 30-39 y | > = 40 y | p for trend | Reference value |
|---|---|---|---|---|---|---|
| WBC Count, 10^3/µL | 5.9 ± 1.8* | 6.2 ± 2.2 | 5.3 ± 1.5 | 5.9 ± 1.7 | 0.880 | 4.0-10.8 |
| RBC Count, 10^6/µL | 4.6 ± 0.5 | 4.4 ± 0.5 | 4.6 ± 0.5 | 4.1 ± 0.4 | 0.094 | 4.5-6.1 |
| Hemoglobin, g/dL | 13.4 ± 1.5 | 13.2 ± 1.3 | 13.6 ± 1.5 | 11.9 ± 1.5 | 0.117 | 13-17 |
| Hematocrit, % | 40.4 ± 4.3 | 39.8 ± 3.8 | 40.9 ± 4.4 | 36.5 ± 4.1 | 0.138 | 40-52 |
| MCV, fL | 88.5 ± 3.4 | 90.8 ± 4.1 | 89.1 ± 5.3 | 89.9 ± 4.1 | 0.720 | 80-98 |
| MCH, pg | 29.4 ± 1.2 | 30.1 ± 1.5 | 29.6 ± 2.2 | 29.4 ± 1.6 | 0.848 | 27-33 |
| MCHC, g/dL | 33.2 ± 0.4 | 33.2 ± 0.8 | 33.2 ± 0.6 | 32.7 ± 1.4 | 0.260 | 33-37 |
| RDW, % | 13.1 ± 0.9 | 13.2 ± 0.8 | 12.9 ± 0.9 | 13.9 ± 1.4 | 0.303 | 11.5-14.5 |
| PDW, fL | 11.6 ± 1.6 | 11.3 ± 2.1 | 11.5 ± 1.8 | 10.9 ± 2.2 | 0.213 | 9-17 |
| MPV, fL | 10.3 ± 0.7 | 10.1 ± 1.0 | 10.1 ± 0.8 | 10.0 ± 1.0 | 0.222 | 7.4-10.4 |
| PLT Count, 10^3/µL | 234.9 ± 75.5 | 230.8 ± 54.8 | 218.7 ± 90.6 | 245.1 ± 91.9 | 0.545 | 150-400 |
| Neutrophil, % | 48.9 ± 12.2 | 61.3 ± 40.6 | 50.5 ± 7.3 | 52.6 ± 10.7 | 0.809 | 40-73 |
| Lymphocyte, % | 39.2 ± 12.0 | 34.8 ± 13.5 | 37.6 ± 5.6 | 36.6 ± 10.7 | 0.801 | 19-48 |
| Monocyte, % | 7.2 ± 1.5 | 8.5 ± 4.8 | 8.3 ± 2.1 | 8.0 ± 2.3 | 0.449 | 0.4-10.0 |
| Eosinophil, % | 4.2 ± 5.2 | 2.5 ± 1.9 | 2.7 ± 1.3 | 2.3 ± 1.6 | 0.650 | 0-7 |
| Basophil, % | 0.5 ± 0.2 | 0.6 ± 0.4 | 0.9 ± 0.5 | 0.5 ± 0.3 | 0.644 | 0-2 |
| ESR, mm/hr | 12.0 ± 15.2 | 20.5 ± 18.1 | 23.5 ± 16.8 | 37.2 ± 19.1 | 0.000† | 0-15 |
WBC: white blood cell, RBC: red blood cell, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, RDW: red cell distribution width, PDW: platelet distribution width, MPV: mean plasma volume, PLT: platelet, ESR: erythrocyte sedimentation rate.
*Mean ± SD; Significance as determined by the Jonckheere-Terpstra test, p for trend less than †p < 0.001.
WHOQOL-BREF scores of subjects
| WHOQOL-BREF domains | 10-19 y | 20-29 y | 30-39 y | > = 40 y | p for trend |
|---|---|---|---|---|---|
| Overall Quality of Life and General Health | 12.7 ± 2.9* | 12.5 ± 3.3 | 12.5 ± 2.4 | 11.3 ± 2.7 | 0.271 |
| Domain 1 Physical health Domain | 12.4 ± 2.3 | 12.2 ± 2.7 | 10.6 ± 2.5 | 9.0 ± 3.2 | 0.004‡ |
| Pain and discomfort | 12.4 ± 4.9 | 13.2 ± 5.3 | 10.5 ± 4.8 | 9.1 ± 4.8 | 0.056 |
| Energy and fatigue | 12.7 ± 4.7 | 12.4 ± 4.1 | 11.6 ± 2.2 | 8.4 ± 3.8 | 0.008‡ |
| Sleep and rest | 13.5 ± 4.8 | 13.3 ± 4.3 | 11.6 ± 3.8 | 12.0 ± 5.7 | 0.264 |
| Mobility | 12.7 ± 5.0 | 11.2 ± 5.2 | 8.0 ± 3.6 | 8.0 ± 3.1 | 0.005‡ |
| Activity of daily living | 12.0 ± 3.6 | 12.8 ± 4.0 | 12.0 ± 3.1 | 9.5 ± 5.1 | 0.171 |
| Dependency on Medication or treatment | 12.4 ± 4.9 | 11.7 ± 4.0 | 10.5 ± 5.1 | 6.9 ± 5.1 | 0.014† |
| Work capacity | 12.0 ± 4.7 | 10.8 ± 4.5 | 10.2 ± 3.3 | 9.1 ± 6.0 | 0.117 |
| Domain 2 Psychological Domain | 13.0 ± 2.9 | 13.3 ± 3.0 | 13.4 ± 2.4 | 11.4 ± 3.2 | 0.359 |
| Positive feelings | 12.4 ± 5.2 | 13.4 ± 3.8 | 13.1 ± 3.1 | 11.3 ± 5.9 | 0.617 |
| Thinking, learning, memory & concentration | 13.5 ± 4.1 | 14.4 ± 4.6 | 15.3 ± 3.9 | 14.2 ± 4.5 | 0.474 |
| Self esteem | 13.5 ± 3.7 | 12.8 ± 4.3 | 11.6 ± 2.8 | 9.5 ± 4.5 | 0.010† |
| Bodily image and appearance | 12.4 ± 4.2 | 12.5 ± 4.0 | 12.0 ± 3.1 | 9.8 ± 6.0 | 0.082 |
| Negative feelings | 13.8 ± 4.9 | 13.1 ± 4.7 | 14.2 ± 4.1 | 12.0 ± 5.1 | 0.736 |
| Religion/spirituality/personal beliefs | 12.4 ± 3.8 | 13.8 ± 4.0 | 14.2 ± 3.7 | 11.6 ± 3.8 | 0.708 |
| Domain 3 Social relationships Domain | 11.9 ± 3.4 | 11.0 ± 3.8 | 10.1 ± 3.2 | 10.8 ± 3.4 | 0.262 |
| Personal relationship | 11.3 ± 3.5 | 11.7 ± 4.0 | 12.0 ± 4.4 | 12.4 ± 4.5 | 0.374 |
| Practical social support | 14.5 ± 4.5 | 11.9 ± 5.6 | 9.8 ± 5.2 | 10.2 ± 5.5 | 0.031† |
| Sexual activity | 13.0 ± 3.5 | 10.4 ± 4.4 | 8.8 ± 3.7 | 9.8 ± 4.5 | 0.105 |
| Domain 4 Environmental Domain | 13.1 ± 2.8 | 13.1 ± 2.0 | 13.4 ± 2.4 | 10.7 ± 3.0 | 0.083 |
| Physical safety and security | 12.7 ± 3.5 | 13.2 ± 4.1 | 13.1 ± 3.1 | 11.3 ± 4.7 | 0.325 |
| Home environment | 12.4 ± 4.2 | 14.4 ± 4.4 | 14.5 ± 2.7 | 12.7 ± 5.3 | 0.600 |
| Financial resources | 10.9 ± 3.6 | 12.1 ± 4.7 | 11.6 ± 4.9 | 7.6 ± 4.2 | 0.088 |
| Health and social care : availability and quality | 13.8 ± 2.8 | 13.9 ± 4.0 | 12.0 ± 2.5 | 12.0 ± 4.4 | 0.097 |
| Opportunities for acquiring new information and skills | 13.8 ± 5.5 | 14.1 ± 3.5 | 16.0 ± 3.6 | 8.7 ± 5.3 | 0.134 |
| Participation and Opportunities for recreation/leisure | 13.5 ± 5.1 | 11.4 ± 4.9 | 12.0 ± 4.4 | 7.6 ± 3.8 | 0.017† |
| Physical environment | 13.1 ± 3.6 | 13.9 ± 3.1 | 16.4 ± 3.3 | 12.7 ± 4.3 | 0.512 |
| Transport | 14.5 ± 4.5 | 11.8 ± 5.4 | 11.3 ± 5.0 | 13.1 ± 6.0 | 0.512 |
| Total | 63.1 ± 11.5 | 62.1 ± 11.6 | 60.0 ± 7.7 | 53.2 ± 12.3 | 0.023† |
WHOQOL-BREF: world health organization quality of life-BREF.
*Mean ± SD; Significance as determined by the Jonckheere-Terpstra test, p for trend less than †p < 0.05; ‡p < 0.01.
Nutritional intakes of subjects
| Variable | 10-19 y | 20-29 y | 30-39 y | > = 40 y | Total |
|---|---|---|---|---|---|
| Energy, kcal | 1253.9 ± 374.3* | 1123.9 ± 382.2 | 1226.7 ± 388.8 | 1090.5 ± 275.0 | 1158.0 ± 365.3 |
| Carbohydrate, g | 175.1 ± 48.6 | 157.3 ± 53.7 | 186.1 ± 67.2 | 163.5 ± 38.2 | 165.9 ± 53.1 |
| Dietary fiber, g | 15.1 ± 4.1 | 13.5 ± 6.2 | 16.9 ± 9.8 | 15.5 ± 6.3 | 14.6 ± 6.6 |
| Total fat, g | 37.5 ± 23.5 | 35.7 ± 17.3 | 33.3 ± 12.2 | 28.1 ± 12.0 | 34.5 ± 17.2 |
| Vegetable fat, g | 16.5 ± 7.2 | 19.5 ± 9.7 | 18.9 ± 10.8 | 15.6 ± 9.7 | 18.3 ± 9.4 |
| Animal fat, g | 21.1 ± 17.5 | 16.2 ± 14.8 | 14.4 ± 10.7 | 12.5 ± 6.4 | 16.2 ± 13.8 |
| Cholesterol, mg | 305.0 ± 278.9 | 236.3 ± 226.9 | 275.9 ± 214.6 | 329.6 ± 210.9 | 269.0 ± 231.0 |
| Total Protein, g | 55.6 ± 17.0 | 46.9 ± 19.6 | 51.2 ± 20.5 | 48.5 ± 13.0 | 49.4 ± 18.4 |
| Plant protein, g | 25.8 ± 7.2 | 23.7 ± 10.1 | 29.2 ± 14.9 | 24.4 ± 7.9 | 25.0 ± 10.2 |
| Animal protein, g | 29.8 ± 16.1 | 23.2 ± 13.7 | 22.0 ± 11.0 | 24.1 ± 8.5 | 24.3 ± 13.2 |
| Vitamin A, ug RE | 505.2 ± 312.5 | 668.2 ± 785.1 | 744.2 ± 644.7 | 717.9 ± 528.8 | 658.0 ± 658.0 |
| Retinol, ug | 105.6 ± 93.1 | 87.6 ± 85.3 | 110.2 ± 96.3 | 119.2 ± 127.9 | 99.1 ± 94.4 |
| β-carotene, ug | 2400.5 ± 1443.4 | 3493.1 ± 4722.2 | 3804.1 ± 3936.1 | 3591.9 ± 3035.5 | 3358.4 ± 3918.6 |
| Vitamin D, ug | 4.1 ± 3.0 | 3.2 ± 4.3 | 4.9 ± 4.7 | 3.4 ± 3.5 | 3.6 ± 4.0 |
| Vitamin E, mg | 10.9 ± 5.6 | 9.8 ± 4.9 | 10.6 ± 5.8 | 10.0 ± 4.9 | 10.1 ± 5.1 |
| Vitamin K, ug | 161.5 ± 129.6 | 206.8 ± 320.1 | 215.6 ± 201.3 | 259.0 ± 260.2 | 207.9 ± 266.1 |
| Vitamin C, mg | 78.3 ± 85.0 | 67.0 ± 53.9 | 67.5 ± 35.3 | 89.2 ± 69.1 | 72.5 ± 60.1 |
| Thiamin, mg | 1.0 ± 0.5 | 0.8 ± 0.5 | 0.8 ± 0.3 | 0.8 ± 0.3 | 0.9 ± 0.4 |
| Riboflavin, mg | 0.9 ± 0.4 | 0.9 ± 0.5 | 1.0 ± 0.5 | 0.9 ± 0.5 | 0.9 ± 0.5 |
| Niacin, mg | 12.4 ± 5.0 | 10.3 ± 5.5 | 8.6 ± 4.6 | 9.7 ± 3.5 | 10.3 ± 5.0 |
| Vitamin B6, ug | 1.1 ± 0.3 | 1.0 ± 0.4 | 1.1 ± 0.6 | 1.1 ± 0.3 | 1.0 ± 0.4 |
| Folate, ug | 458.1 ± 169.2 | 394.1 ± 262.6 | 449.8 ± 242.2 | 460.7 ± 249.8 | 424.3 ± 240.5 |
| Vitamin B12, ug | 5.9 ± 4.5 | 7.1 ± 5.2 | 8.9 ± 5.9 | 12.4 ± 8.0 | 8.0 ± 6.0 |
| Pantothennic acid, mg | 4.1 ± 1.2 | 3.5 ± 1.2 | 4.3 ± 1.6 | 3.3 ± 0.8 | 3.7 ± 1.3 |
| Biotin, ug | 16.8 ± 13.6 | 14.6 ± 12.8 | 16.2 ± 12.9 | 16.0 ± 11.4 | 15.4 ± 12.5 |
| Total Calcium, mg | 398.6 ± 190.4 | 378.7 ± 147.1 | 528.9 ± 321.7 | 426.8 ± 157.7 | 412.6 ± 194.8 |
| Animal Calcium, mg | 202.6 ± 87.0 | 191.4 ± 112.6 | 248.8 ± 156.9 | 195.6 ± 82.4 | 202.8 ± 111.9 |
| Vegetable Calcium, mg | 196.0 ± 165.4 | 187.3 ± 108.9 | 280.1 ± 352.8 | 231.2 ± 129.5 | 209.8 ± 177.9 |
| Phosphorus, mg | 862.4 ± 277.8 | 721.8 ± 251.7 | 860.7 ± 325.8 | 788.5 ± 179.3 | 778.6 ± 262.0 |
| Sodium, mg | 3174.3 ± 966.1 | 2730.7 ± 1545.7 | 2727.1 ± 1897.8 | 3514.3 ± 1356.7 | 2929.9 ± 1492.2 |
| Chloride, mg | 356.0 ± 317.1 | 445.8 ± 962.3 | 373.4 ± 411.9 | 209.2 ± 116.2 | 382.4 ± 720.6 |
| Potassium, mg | 1860.9 ± 552.2 | 1732.2 ± 727.7 | 2129.0 ± 1020.6 | 1867.0 ± 561.2 | 1836.7 ± 728.2 |
| Magnesium, mg | 57.4 ± 35.4 | 49.6 ± 31.9 | 55.0 ± 38.1 | 47.3 ± 22.6 | 51.5 ± 31.9 |
| Total iron, mg | 9.6 ± 2.4 | 11.7 ± 9.2 | 10.9 ± 5.5 | 10.2 ± 3.2 | 10.9 ± 7.1 |
| Animal iron, mg | 7.1 ± 1.9 | 8.8 ± 8.6 | 8.8 ± 4.8 | 7.5 ± 2.7 | 8.3 ± 6.5 |
| Vegetable iron, mg | 2.5 ± 1.6 | 2.8 ± 2.6 | 2.1 ± 1.1 | 2.7 ± 1.5 | 2.6 ± 2.1 |
| Zinc, mg | 7.6 ± 2.5 | 6.4 ± 2.5 | 6.9 ± 2.2 | 6.8 ± 1.8 | 6.8 ± 2.3 |
| Copper, mg | 0.8 ± 0.3 | 0.8 ± 0.4 | 0.9 ± 0.4 | 0.8 ± 0.2 | 0.8 ± 0.3 |
| Fluorine, ug | 5.9 ± 9.2 | 9.0 ± 24.6 | 3.6 ± 7.8 | 4.1 ± 4.6 | 6.9 ± 18.4 |
| Manganese, mg | 2.8 ± 0.7 | 2.3 ± 1.2 | 2.9 ± 1.3 | 2.9 ± 0.7 | 2.6 ± 1.1 |
| Iodine, ug | 92.3 ± 68.0 | 325.6 ± 792.2 | 179.1 ± 230.0 | 557.0 ± 745.7 | 296.4 ± 652.3 |
| Selenium, ug | 86.0 ± 36.1 | 70.9 ± 37.9 | 69.8 ± 28.8 | 71.8 ± 26.0 | 73.6 ± 34.6 |
*Mean ± SD.
Bioelectrical impedance analysis (BIA) data of subjects
| Variable | 10-19 y | 20-29 y | 30-39 y | > = 40 y | p for trend |
|---|---|---|---|---|---|
| PhA, ° | 2.62 ± 0.87* | 2.45 ± 0.75 | 2.84 ± 0.99 | 2.30 ± 0.70 | 0.671 |
| Intracellular water (ICW), L | 9.9 ± 3.1 | 10.5 ± 2.8 | 11.0 ± 3.3 | 13.5 ± 2.9 | 0.009‡ |
| Extracellular water (ECW), L | 7.4 ± 2.2 | 7.4 ± 1.9 | 8.0 ± 2.5 | 9.7 ± 2.0 | 0.014† |
| Total body water (TBW), L | 17.3 ± 5.3 | 17.9 ± 4.4 | 19.0 ± 5.9 | 23.1 ± 4.8 | 0.006‡ |
| ECW/TBW | 0.429 ± 0.014 | 0.415 ± 0.046 | 0.419 ± 0.010 | 0.418 ± 0.009 | 0.026 |
| %TBW/FFM, % | 71.4 ± 2.3 | 71.9 ± 1.9 | 72.9 ± 2.0 | 73.6 ± 0.8 | 0.000§ |
| Protein, kg | 4.3 ± 1.4 | 4.5 ± 1.2 | 4.8 ± 1.5 | 5.8 ± 1.3 | 0.009‡ |
| Mineral, kg | 2.5 ± 0.6 | 2.4 ± 0.5 | 2.2 ± 0.6 | 2.4 ± 0.4 | 0.721 |
| Soft lean mass (SLM), kg | 21.8 ± 6.7 | 22.7 ± 5.7 | 24.2 ± 7.4 | 29.3 ± 6.2 | 0.010† |
| Fat free mass (FFM), kg | 24.1 ± 6.8 | 24.8 ± 6.0 | 26.0 ± 7.6 | 31.4 ± 6.3 | 0.010† |
| Fat mass (FM), kg | 12.5 ± 13.7 | 13.5 ± 11.4 | 20.6 ± 14.5 | 28.3 ± 13.8 | 0.001‡ |
| %Body fat (%BF), % | 29.0 ± 18.9 | 30.4 ± 17.8 | 39.5 ± 13.3 | 44.3 ± 14.3 | 0.014† |
| Skeletal muscle mass (SMM), kg | 10.9 ± 4.1 | 11.6 ± 3.6 | 12.4 ± 4.4 | 15.6 ± 3.8 | 0.009‡ |
| Body cell mass (BCM), kg | 14.2 ± 4.4 | 15.0 ± 3.9 | 15.8 ± 4.8 | 19.3 ± 4.2 | 0.009‡ |
| Bone mineral content (BMC), kg | 2.2 ± 0.6 | 2.1 ± 0.5 | 1.9 ± 0.5 | 2.1 ± 0.3 | 0.446 |
PhA: phase angle, between 3° and 15° in the majority of human beings, ECW/TBW: extracellular water/total body water, TBW/FFM: total body water/fat free mass.
*Mean ± SD; Significance as determined by the Jonckheere-Terpstra test, p for trend less than †p < 0.05; ‡p < 0.01; §p < 0.001.